The Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC) is an organization composed of neuro-ophthalmologists and other doctors, structured to perform prospective clinical research. Neuro-Ophthalmology is a subspecialty of Neurology and Ophthalmology that addresses scientific and medical aspects that bridge both specialties. There is a broad spectrum of Neuro-ophthalmologic disorders that collectively affect millions of people. Many of these are visual disorders associated with other systemic or neurological conditions and many fit the US Government definition as """"""""rare"""""""" diseases and have not been adequately investigated. The Network is prepared to conduct studies on two of these disorders: idiopathic intracranial hypertension and thyroid eye disease. There is little consensus among practitioners on the diagnostic evaluation or therapy for many neuro-ophthalmological disorders. NORDIC will provide the organization and operational capability to perform multi-site observational and treatment trials, involving nearly 200 community and academic practitioners, in order to address the many crucial yet unanswered questions about risks, diagnosis, treatment and other management-aspects of these diseases that could not be studied without a clinical research organization. The NORDIC strategy is to provide a strong Central Coordination, to an open network of investigators at sites, in order to conduct multiple trials in parallel, employing protocols that can be incorporated into standard clinical practice. The strong central coordination is provided by: the NORDIC Chair and Executive Committee who are recognized leaders in neuroophthalmic and clinical research;the use of steering committees for each study;a Data Coordination and Biostatistics Center that is expert at national, multi-site studies;and reading centers appropriate for neuroophthalmic assessments. The open network and structure will allow practitioners to develop new studies, become certified and participate in specific studies and protocols, as appropriate to their expertise and interests. This approach will allow the recruitment and study of powerful numbers of otherwise-hard-to-find study patients, with a high degree of control over the scientific quality of the research projects. The products of the NORDIC strategy will be evidence-based diagnostic and treatment solutions that can be applied to enhance the visual health of a significant portion of the population.

National Institute of Health (NIH)
National Eye Institute (NEI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZEY1-VSN (05))
Program Officer
Schron, Eleanor
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
St. Luke's-Roosevelt Institute for Health Sciences
New York
United States
Zip Code
Friedman, Deborah I; Quiros, Peter A; Subramanian, Prem S et al. (2017) Headache in Idiopathic Intracranial Hypertension: Findings From the Idiopathic Intracranial Hypertension Treatment Trial. Headache 57:1195-1205
Wang, Jui-Kai; Kardon, Randy H; Ledolter, Johannes et al. (2017) Peripapillary Retinal Pigment Epithelium Layer Shape Changes From Acetazolamide Treatment in the Idiopathic Intracranial Hypertension Treatment Trial. Invest Ophthalmol Vis Sci 58:2554-2565
Kupersmith, Mark J; Sibony, Patrick A; Dave, Sarita (2017) Nonarteritic Anterior Ischemic Optic Neuropathy Induced Retinal Folds and Deformations. Invest Ophthalmol Vis Sci 58:4286-4291
Wall, Michael; Kupersmith, Mark J; Thurtell, Matthew J et al. (2017) The Longitudinal Idiopathic Intracranial Hypertension Trial: Outcomes From Months 6-12. Am J Ophthalmol 176:102-107
Kupersmith, Mark J; Sibony, Patrick A; Feldon, Steven E et al. (2017) The Effect of Treatment of Idiopathic Intracranial Hypertension on Prevalence of Retinal and Choroidal Folds. Am J Ophthalmol 176:77-86
Libien, J; Kupersmith, M J; Blaner, W et al. (2017) Role of vitamin A metabolism in IIH: Results from the idiopathic intracranial hypertension treatment trial. J Neurol Sci 372:78-84
Wall, Michael; Thurtell, Matthew J; NORDIC Idiopathic Intracranial Hypertension Study Group (2017) Optic disc haemorrhages at baseline as a risk factor for poor outcome in the Idiopathic Intracranial Hypertension Treatment Trial. Br J Ophthalmol 101:1256-1260
Peragallo, Jason H; Bitrian, Elena; Kupersmith, Mark J et al. (2016) Relationship Between Age, Gender, and Race in Patients Presenting With Myasthenia Gravis With Only Ocular Manifestations. J Neuroophthalmol 36:29-32
Wall, Michael; Johnson, Chris A; Cello, Kimberly E et al. (2016) Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Invest Ophthalmol Vis Sci 57:805-12
Kupersmith, Mark J; Garvin, Mona K; Wang, Jui-Kai et al. (2016) Retinal ganglion cell layer thinning within one month of presentation for optic neuritis. Mult Scler 22:641-8

Showing the most recent 10 out of 37 publications